Empower Clinics Inc.
Strong 2021 Fiscal Performance Supporting Robust Clinic, Testing Expansion and Acquisition Efforts
VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - is pleased to provide the following corporate update on our national clinic expansion strategy and overview of other corporate endeavors.
"This corporate update is a testament to the growth of Empower Clinics over the last year," said Steven McAuley, Chairman & CEO of Empower. "Our national clinic expansion strategy will provide enhanced access to healthcare for millions of Canadians. We continue to make meaningful strides across our network with various Kai Care testing partnerships and its recent expansion allowing for greater volume and diversification of services. We are also thrilled to have completed the MediSure acquisition and look forward to leveraging our collective network to drive increased volume and new product development."
Clinic Pipelines
The Company is pleased to provide shareholders with an update on its progress of opening new clinics locations that are now in various stages ranging from LOI's, to leases signed, construction underway and opening dates pending.
SIGNED LEASES with construction underway
1) Etobicoke,ON
2) London, ON
3) Etobicoke, ON 2nd flagship location
4) Hamilton, ON
LEASES signed
1) Hamilton, ON Rexall proximity
2) Kitchener, ON Rexall proximity
3) Ajax, ON Rexall proximity
4) Barrie, ON Rexall proximity
PENDING LOI'S & LEASES
1) Sudbury, ON Pharmacy proximity
2) Chatham, ON Pharamcy proximity
3) Nepean, ON Pharmacy proximity
4) Peterborough, ON Pharmacy proximity
5) St. Catherines, ON
Chairman & CEO Mr. McAuley added, "I simply want to say that our Canadian health centre development plan has never been in doubt for us, from the moment we announced the strategy. Working so closely on a plan with pharmacy organizations takes time to materialize, it requires a collective effort with all constituents, but as everyone knows, we have not been idle, we have not been complacent, we have been diligent, respectful and focused on building a long-term strategy. I am so impressed with our business development team and their recruitment of medical doctors to date, that will serve so many communities and neighbourhoods. We seem to be building a collective of healthcare centers, a collective of medical professionals, a collective of knowledge and expertise, focused on the health outcomes of people in the markets we serve."
Acquisitions
Empower Clinics recently finalized the acquisition of leading Canadian diabetic service manufacturing company MediSure. With over $1.9M in revenue for 2020, 50,000 end users and presence in over 4,000 Canadian pharmacies, MediSure represents a highly valuable asset for the Empower Network.
Partnerships
Empower Clinics has signed nine partnership agreements in 2021 with leading companies across Canada and the United States. Each partnership leverages various strengths of the Empower Clinics network. The endeavours include:
- Signed partnership to offer COVID-19 testing on a long-term basis for the Dallas Market Centre
- Signed partnership for select clinics to offer the MedX DermSecure screening platform
- Signed referral agreement with major Canadian airline for Kai Care COVID testing
- Signed partnered with Loop Insights to augment COVID mitigation efforts through testing
- Signed partnership with PharmaChoice to carry Kai Care saliva test kits, Antigen Tests & Antibody Tests in their more than 900 independent pharmacies across Canada
- Signed partnership with Save-On-Foods to sell Kai Saliva tests in Vancouver area stores
- Signed partnership with Tabula Rasa Pharmacy for a dedicated 24-hour customer support line
Financials
Empower Clinics has had a tremendous year of growth that has translated to promising fiscal results. A 58% year-over-year growth and a zero cash loss in 2020 set Empower up to make significant strides in 2021. Empower yielded over $2.5M of revenue in Q1 2021, a 258% growth compared to 2020.
Corporate Talent
Along with tremendous fiscal growth, Empower Clinics is looking to elevate its corporate leadership team and partnerships. Recently retained global executive recruiting firm Korn Ferry has started searching for a new Chief Financial Officer (CFO). An immediate priority for the new executive will be an in-depth review of current financial and audit operations, with the express intent to make recommendations to affect positive change on current practices and partnerships.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146
Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/659317/Empower-Clinics-Provides-Corporate-Update-On-National-Clinic-Expansion
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models8.7.2025 14:30:00 CEST | Press release
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically r
Karbon-X Becomes Official Name Sponsor of BK Dukes Basketball Team8.7.2025 09:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / July 8, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has signed a multi-year agreement to become the official name sponsor of BK Dukes, one of Austria's top professional basketball teams. Effective immediately, the team will compete as the BK Karbon-X Dukes. This partnership brings together two high-performance organizations committed to community, innovation, and progress chon and off the court. Fresh off their 2024-2025 Austrian Cup Title win, the BK Dukes are working with Karbon-X to integrate measurable sustainability initiatives throughout the organization. This includes annual emissions reporting, offsetting all team and venue Scope 1, 2, and 3 emissions, and incorporating an emissions offset fee into every ticket purchase to address fan-related impacts. Together, they are building a model of leadership that extends far beyond the scoreboard. "This partnership represents what climate action should look like
Polaris Renewable Energy Announces Q1 2025 Investor Call Details7.7.2025 22:10:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 7, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2025 Earnings Results on Thursday, July 31st, 2025, at 10:00 am EST. To listen to the call, please dial Toll Free 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 108489. or URL: https://www.webcaster4.com/Webcast/Page/2773/51833 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51833 International (toll-free): 1 919-882-2331, Passcode: 51833 Encore Replay Expiration Date: August 14, 2025 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing an
Innodata to Report Second Quarter 2025 Results7.7.2025 14:30:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / July 7, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Second Quarter 2025 results after the market closes on Thursday, July 31, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+1) 289 819 1520 International Participant Access Code 18067# Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the conference call, at the Investor Relations sect
GoodData Launches AI for Self-Hosted Analytics: Powerful, Proven, Private7.7.2025 14:30:00 CEST | Press release
GoodData AI capabilities, including AI Assistant and Smart Search, now available for self-hosted deployment. Keep your data private, compliant, and AI-fuelled. SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / July 7, 2025 / GoodData, the AI-native analytics platform, today announced GoodData AI is now available for self-hosted deployment. Enterprises can now run GoodData AI, including AI Assistant and Smart Search, entirely within their own infrastructure - on-premises or in a private cloud - with zero third-party data exposure. With this launch, GoodData delivers the full promise of AI-driven analytics while honoring the strict privacy, compliance, and control requirements of modern enterprises. Self-hosting gives organizations total ownership of their analytics workflows, from natural language queries to insight generation, all within their secure perimeter. "Enterprises shouldn't have to choose between innovation and control. With self-hosted GoodData AI, we're giving our customers the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom